MGMT Methylation Correlates With Melphalan Pelvic Perfusion Survival in Stage III Melanoma Patients

Melanoma Research - United States
doi 10.1097/cmr.0000000000000367
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Ovid Technologies (Wolters Kluwer Health)

Related search

Methylation of MGMT Is Associated With Poor Prognosis in Patients With Stage III Duodenal Adenocarcinoma

PLoS ONE
Multidisciplinary
2016English

Review of Regional Limb Perfusion With Melphalan for Malignant Melanoma

BMJ
1966English

Melphalan Tissue Concentrations in Patients Treated With Regional Isolated Perfusion for Melanoma of the Lower Limb

British Journal of Cancer
Cancer ResearchOncology
1994English

Preoperative BRAF Inhibition in Patients With Irresectable Locally Advanced Stage III Melanoma

Melanoma Management
DermatologyOncology
2018English

Twelve-Year Survival and Immune Correlates in Dendritic Cell–vaccinated Melanoma Patients

JCI insight
Medicine
2017English

Low Levels of Quantified MGMT Methylation Status Impart Positive Impact on Survival

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2019English

Antibody Response to Melanoma Helper-Peptide Vaccine Correlates With Survival

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2013English

The Effect of Temperature and Perfusion Time on Response, Toxicity, and Survival in Patients With In-Transit Melanoma Metastases Treated With Isolated Limb Perfusion

Annals of Surgical Oncology
OncologySurgery
2018English

Chemosaturation With Percutaneous Hepatic Perfusion of Melphalan for Liver-Dominant Metastatic Uveal Melanoma: A Single Center Experience

Cancer Imaging
Nuclear MedicineRadiologyUltrasound TechnologyOncologyRadiologicalImagingMedicine
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy